Basel, Switzerland
Versameb AG, founded in 2017 and based in Switzerland, is at the forefront of the biotechnology and pharmaceutical industries, focusing on RNA therapeutics. Their innovative approach centers on developing breakthrough RNA-based drugs that modulate protein expression with precision and target multiple therapeutic areas through a single molecular construct.
The company's proprietary platform, VERSagile, stands out for optimizing functional RNA usage in disease contexts traditionally deemed challenging. Spearheaded by a knowledgeable scientific and leadership team, Versameb AG boasts promising projects in its pipeline, including initiatives targeting Stress Urinary Incontinence (SUI) and solid tumors. Currently, they are progressing towards a first in-human proof-of-concept clinical study to validate their platform's capabilities.
Their latest financial milestone was a Fr.8.99M Seed Round investment secured on June 14, 2023, led by Bernina BioInvest. This capital is instrumental in advancing their clinical endeavors and further refining their proprietary technology.
